Botox and Daxxify are both botulinum toxin type A, but Daxxify is built to last longer, often around six months versus three to four for Botox. Compare onset, formulation, FDA approvals, safety, and cost to decide which fits you.
Botox and Daxxify are both botulinum toxin type A injectables that relax muscles to soften frown lines. The core difference is duration: Daxxify's peptide stabilizer helps it last around six months versus three to four for Botox. Botox costs less per session and has a far longer safety record.
Botox and Daxxify sit in the same drug family, botulinum toxin type A, and do the same basic job: they temporarily block the nerve signal that tells a muscle to contract, so the overlying skin creases less and lines soften. If you have compared quotes or read a clinic menu, the headline pitch for Daxxify is almost always the same, that it lasts longer than Botox. That claim is real, but it comes with trade-offs in cost, track record, and how the longer duration actually plays out for different people.
This guide breaks down what the two share, where they genuinely differ, what the clinical evidence says about duration, how safety and side effects compare, and what drives the price difference. The honest bottom line up front: neither is universally better. Daxxify can mean fewer appointments a year, while Botox is the lower-cost, decades-proven option. The right pick depends on your goals, your budget, and how you respond to treatment, which is why the injector you choose matters more than the brand on the box.
Both products are neuromodulators, both are given as a quick series of injections into targeted facial muscles, and both are FDA-approved for the frown lines between the brows. The table below summarizes the practical differences most people are weighing. Treat the numbers as typical ranges, not promises, because duration, onset, and price all vary with the dose used, the area treated, your individual metabolism, and your provider.
| Attribute | Botox | Daxxify |
|---|---|---|
| Active ingredient | onabotulinumtoxinA | daxibotulinumtoxinA-lanm |
| Manufacturer | AbbVie (Allergan Aesthetics) | Revance Therapeutics |
| Stabilizer | Human serum albumin | 35 amino acid peptide (RTP004), no human or animal proteins |
| Typical onset | 3 to 5 days | 1 to 3 days |
| Typical duration | 3 to 4 months | About 6 months (median in trials) |
| FDA cosmetic approval | Glabellar (frown) lines | Glabellar (frown) lines |
| Other FDA uses | Many (medical and cosmetic) | Cervical dystonia |
| Track record | Since 2002 (cosmetic) | Since 2022 |
| Relative cost | Lower per session | Higher per session |
The similarities matter as much as the differences, because they explain why results in skilled hands look alike. Both are purified botulinum toxin type A, the same class of molecule, and both work by the identical mechanism: they inhibit the release of acetylcholine at the neuromuscular junction, which prevents the treated muscle from fully contracting. That is why a frown, forehead lift, or crow's feet squint softens after either product.
The patient experience is also similar. Each is a series of small injections that takes only a few minutes, needs no anesthesia beyond optional topical numbing or ice, and lets you return to normal activity the same day with brief redness or tiny bumps at the injection points. Aftercare advice overlaps too: most injectors ask you to stay upright, avoid rubbing the area, and skip strenuous exercise for the rest of the day. Neither product is permanent, so both require repeat treatment to maintain the effect. And both carry the same class-wide FDA boxed warning about the rare risk of toxin spreading beyond the injection site. In short, this is not a comparison of a strong toxin against a weak one. It is a comparison of two effective toxins formulated and dosed differently.
The most meaningful difference is in the stabilizer wrapped around the toxin. Botox uses human serum albumin, a blood-derived protein, to keep the molecule stable. Daxxify replaces that with a proprietary 35 amino acid peptide called RTP004, which contains no human or animal-derived components. That peptide is engineered to bind the toxin and is the feature Revance credits for the longer duration, because it appears to keep more active toxin at the target for longer. The peptide formulation is also why Daxxify is sometimes marketed to people who prefer to avoid albumin, though there is no evidence that albumin in Botox is unsafe.
Onset differs modestly. Many patients notice Daxxify starting to work in one to three days, while Botox typically takes three to five days, with full effect for either around two weeks. If you have an event on a tight timeline, the faster onset can be a small plus, but the difference is measured in days, not weeks. Dosing is not interchangeable between the two: Daxxify is measured in its own units and administered per its own guidance, so you cannot assume a one-to-one unit swap from a Botox plan. In the pivotal frown-line trials, Daxxify was studied at a 40 unit dose, and your injector will dose to the product and to your anatomy, not to a conversion chart.
This is the headline claim and the reason most people consider Daxxify, so it deserves a careful look. Botox for frown lines is generally cited as lasting three to four months before the muscle regains movement and lines return. Daxxify was designed to last longer, and the manufacturer positions it around six months. The claim is backed by real Phase 3 data rather than marketing alone, which is important for a decision like this.
In the SAKURA 1 and SAKURA 2 pivotal trials, a single 40 unit treatment produced a strong response at week four, and roughly half of treated patients still had none or only mild frown lines at 24 weeks, about six months, from one treatment. The larger open-label SAKURA 3 safety study supported repeat dosing over time. The honest caveat is that median is not everyone: in the same trials, the median time to return of visible frown lines was in the range of about five to six months, and plenty of people fell below that. Duration also depends heavily on the treated area, the dose, and how quickly your body metabolizes toxin. The frown region is where the six-month figure is best supported. For other areas, which are off-label for both products, longevity is less established. So Daxxify does last longer on average, but a longer-lasting result is a probability, not a guarantee, and individual mileage varies.
Both products are FDA-approved for the same cosmetic indication: moderate to severe glabellar lines, the vertical frown lines between the eyebrows caused by the corrugator and procerus muscles. Daxxify received that cosmetic approval in September 2022 and is also FDA-approved for cervical dystonia, a medical condition. Botox has a much broader approved footprint built over two decades, including forehead lines and crow's feet cosmetically, plus numerous medical uses such as chronic migraine, excessive sweating, overactive bladder, and muscle spasticity.
This matters for honesty about how the products are commonly used. When either toxin is injected into the forehead lines, crow's feet, a lip flip, a gummy smile, jaw slimming, or a neck lift, that use is off-label for Daxxify, and for several of those areas off-label for Botox as well. Off-label does not mean unsafe or improper. It is a routine, legal part of aesthetic practice, and experienced injectors treat these areas every day. It simply means the manufacturer has not sought FDA approval for that specific site, so the marketing claims and, for Daxxify, the strongest duration data apply mainly to the frown lines. A good provider will tell you plainly which of your requested areas are on-label and which are off-label before treating.
Because they are the same class of drug, Botox and Daxxify share a similar safety profile. The most common side effects are mild and local: temporary redness, swelling, bruising, or small bumps at the injection sites, and sometimes a headache after treatment. The side effect that worries people most is a droopy eyelid or uneven brow, which usually results from toxin affecting a nearby muscle. This is generally technique-related and temporary, resolving as the product wears off, which is one reason a skilled injector matters.
Both products carry the FDA boxed warning that applies to all botulinum toxins: in rare cases the toxin can spread beyond the injection site and cause symptoms such as trouble swallowing, breathing, or muscle weakness, which can be serious. At cosmetic doses in healthy adults this is very uncommon, but it is why these are prescription-only treatments given by a qualified medical professional, not a spa novelty. One nuance worth noting: because Daxxify tends to last longer, an unwanted result such as a heavy brow or asymmetry may also persist longer before it fades. That is a reasonable reason for first-timers to be cautious about committing to the longer-lasting option before they know how they respond. Anyone pregnant, breastfeeding, or with a neuromuscular disorder should avoid both and discuss alternatives with a physician.
Daxxify generally costs more per treatment than Botox. Exact prices vary widely by region, clinic, provider experience, and how much product your treatment requires, so any single number is misleading. As a rough guide, a frown-line treatment with Daxxify often runs higher per session than a comparable Botox treatment, and clinics may price Daxxify per treatment area rather than strictly per unit. We will not quote a fixed price, because pricing is set locally and changes; ask your provider for a written quote for your specific plan.
The smarter way to compare is cost per month of effect rather than sticker price. If Daxxify lasts roughly six months and Botox roughly three to four, one Daxxify session may cover the span of nearly two Botox sessions, which can narrow or even close the per-month gap for some people. Beyond the math, the real value of the higher price is convenience: fewer appointments, less scheduling, and fewer needle days per year. That trade favors busy people who dislike frequent touch-ups. It favors Botox if you are budget-focused, new to toxin and want a shorter commitment, or you want to keep the flexibility to adjust your dose more often. Watch for per-unit price comparisons across brands, which can be misleading because units are not equivalent between products.
Choose based on your priorities rather than the marketing. Daxxify tends to suit people who want the longest stretch between appointments, who have found that Botox wears off faster than they would like, or who prefer a formulation without human or animal-derived proteins. Botox tends to suit first-timers who want a shorter commitment while they learn how they respond, budget-conscious patients, and anyone treating the many areas and medical conditions where Botox has the deeper track record and broader approvals. Neither choice is a mistake, and many injectors keep both on hand and match the product to the area and the patient.
The single most important decision is not the brand but the person holding the syringe. Botulinum toxin results depend on precise anatomical dosing and placement, and a longer-lasting product raises the stakes on getting that right the first time. Look for a licensed medical provider, an experienced injector, a clear conversation about which areas are on-label versus off-label for your plan, and a written price quote. Ask how they would dose each product for your face and why they are recommending one over the other. If you are ready to move forward, the next step is to find a qualified, verified injector near you who offers the product you are leaning toward and can tailor the plan to your goals.
Daxxify lasts longer on average. In pivotal frown-line trials, about half of patients kept none or only mild lines at 24 weeks (roughly 6 months) from one treatment, versus 3 to 4 months typical for Botox. Duration still varies by dose, area, and metabolism.
Daxxify usually costs more per session than Botox. Exact prices vary by region, clinic, provider, and how much product you need, so ask for a written quote. Because Daxxify lasts longer, comparing cost per month of effect is fairer than comparing sticker price.
Not necessarily. Daxxify is measured in its own units and dosed per its own guidance, not converted one-to-one from a Botox plan. In frown-line trials it was studied at 40 units. Your injector doses to the product and your anatomy, not a conversion chart.
It costs more per session and has a shorter track record than Botox (approved 2022). Because it lasts longer, an unwanted result like a heavy brow may also persist longer before fading. Most other approved areas beyond frown lines are off-label, like several Botox uses.
Neither is universally better. Daxxify offers longer duration and fewer appointments; Botox offers lower cost, a longer safety record, and more approved uses. The best choice depends on your goals and budget, and the injector's skill matters more than the brand.